86880

Antihuman globulin test (Coombs test); direct, each antiserum

The CPT code 86880 represents the direct antihuman globulin test, historically and commonly known as the direct Coombs test or the direct antiglobulin test (DAT). This critical laboratory procedure is designed to detect the presence of antibodies (such as IgG) or complement system proteins (specifically C3d) that are bound directly to the surface of a patient's red blood cells (RBCs) in vivo. The binding of these immunoglobulins or complement proteins to RBCs can lead to the premature destruction of the cells, resulting in a condition known as hemolytic anemia. The test is fundamental in investigating various hematologic anomalies and clinical scenarios, most notably suspected autoimmune hemolytic anemia (AIHA), hemolytic disease of the fetus and newborn (HDFN), acute or delayed blood transfusion reactions, and drug-induced immune hemolytic anemia. During the procedure, a blood sample is collected from the patient, usually in an EDTA tube to prevent in vitro complement attachment. The patient's red blood cells are separated from the plasma and thoroughly washed multiple times in a saline solution to remove any unbound, free-floating immunoglobulins or complement proteins that could neutralize the test reagent and cause a false-negative result. Following the washing phase, antihuman globulin (AHG) reagent, also known as Coombs reagent, is added to the washed RBC suspension. The AHG reagent contains antibodies directed against human immunoglobulins, human complement, or both. The mixture is then centrifuged to promote cell-to-cell contact. After centrifugation, the technician or automated system carefully examines the suspension for hemagglutination (clumping) or hemolysis. If the patient's red blood cells are coated with antibodies or complement, the AHG reagent will form cross-links between the cells, causing visible agglutination. This constitutes a positive direct Coombs test. The designation 'each antiserum' in the code descriptor is highly significant for accurate coding and billing. It indicates that if the initial test using a polyspecific antiserum (which screens for both IgG and C3d) yields a positive result, the laboratory will typically reflex to perform separate tests using monospecific antisera (anti-IgG and anti-C3d) to pinpoint the exact nature of the RBC-coating proteins. Under these circumstances, CPT code 86880 may be reported for each distinct antiserum utilized during the testing process, reflecting the additional resources and separate analytical steps required for comprehensive characterization of the immune reaction.

Clinical Indications

  • Suspected autoimmune hemolytic anemia (AIHA).
  • Investigation of a suspected acute or delayed hemolytic transfusion reaction.
  • Diagnosis of hemolytic disease of the fetus and newborn (HDFN).
  • Evaluation of drug-induced immune hemolytic anemia (e.g., penicillin, methyldopa).
  • Unexplained jaundice, pallor, or rapidly dropping hemoglobin or hematocrit levels.
  • Pre-transfusion compatibility testing when a patient exhibits a positive auto-control anomaly.

Procedure Steps

  1. Collect a whole blood sample from the patient via venipuncture, typically utilizing an EDTA (lavender top) tube to prevent in vitro complement binding.
  2. Centrifuge the whole blood sample to separate the red blood cells (RBCs) from the plasma.
  3. Prepare a 2 to 5 percent suspension of the patient's RBCs in isotonic saline.
  4. Wash the RBC suspension three to four times with large volumes of normal saline to completely remove any unbound serum proteins that could neutralize the antihuman globulin reagent.
  5. Decant the final wash completely to ensure a dry cell button.
  6. Add the specific antihuman globulin (AHG) reagent (e.g., polyspecific, anti-IgG, or anti-C3d antiserum) to the washed RBC button.
  7. Gently mix the suspension and centrifuge at the specified speed and duration according to standard operating procedures.
  8. Examine the RBC button macroscopically and microscopically for signs of agglutination (clumping).
  9. Grade the degree of agglutination (e.g., from 1+ to 4+) or note hemolysis, and record the results.
  10. Add Coombs control cells (check cells) to all negative tubes to validate the effectiveness of the AHG reagent and confirm the negative result.

Coding Guidelines

  • Report CPT code 86880 for each individual antiserum used during the direct Coombs testing process. If a polyspecific reagent is used first, followed by monospecific anti-IgG and anti-C3d reagents, the code may be billed multiple times.
  • Append modifier 59 or 91 if multiple, distinct antisera are tested on the same date of service, depending on payer-specific policies regarding multiple units of 86880.
  • Do not confuse 86880 (direct Coombs) with 86881 or 86882 (indirect Coombs test). The direct test checks for in vivo coating of RBCs, while the indirect test checks for free-floating antibodies in the serum or plasma.
  • When reporting multiple units for the use of polyspecific and subsequent monospecific antisera, ensure medical necessity documentation clearly supports the reflex testing.
  • Review National Correct Coding Initiative (NCCI) edits to ensure 86880 is not inappropriately bundled into a larger panel or procedure code without appropriate modifiers if performed independently.

Associated ICD-10 Codes